Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-40279 in Advanced Gastric or Gastroesophageal Junction Cancer
NCT05395780Phase 2Unknown
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nefextinib in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Guangzhou Zaiji Medical Technology. Status: unknown.
02
Drugs
nefextinib
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05395780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395780.